Unicycive Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing novel therapies for kidney diseases, including hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis and acute kidney injury (AKI). The company's lead investigational treatment, oxylanthanum carbonate (OLC), is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology that reduces pill burden through smaller, swallowable pills versus chewed alternatives; OLC has received a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025 from the U.S. Food and Drug Administration (FDA), following a Complete Response Letter (CRL) on June 30, 2025, with plans to resubmit the New Drug Application (NDA) by year-end 2025. Its second pipeline candidate, UNI-494, is a novel nicotinamide ester derivative and selective ATP-sensitive mitochondrial potassium channel activator designed to restore mitochondrial function for AKI treatment, potentially addressing an unmet need with no approved therapies currently available. Unicycive Therapeutics maintains license and development agreements with partners including Shilpa Medicare Ltd. for manufacturing and supply of OLC, Sphaera Pharma Pte. Ltd. for UNI-494, Lee's Pharmaceutical (HK) Limited and Lotus International Pte Ltd. for OLC commercialization in select Asian markets such as Mainland China and Hong Kong, and Syneos Health LLC for UNI-494 development support. Recent strategic developments include a $50 million private placement financing in March 2024 led by Octagon Capital and Great Point Partners to advance OLC toward approval and commercialization, a 1:10 reverse stock split effective June 20, 2025 to regain Nasdaq compliance confirmed on July 7, 2025, and RA Capital Management's acquisition of approximately 10 million shares representing a 9.99% stake as of September 30, 2024. The company reported $42.7 million in cash as of September 30, 2025, providing runway into 2027 to support OLC resubmission, potential approval, commercialization preparations, and UNI-494 advancement. Founded in 2016 and headquartered in Los Altos, California, Unicycive Therapeutics targets patients with CKD and AKI primarily in the United States, with strategic partnerships expanding potential access in Asia.
Company News
UNCY DEADLINE: SueWallSt Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
UNICYCIVE DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY
UNCY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Deadline Alert: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026
UNICYCIVE DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
UNICYCIVE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Kaplan Fox Advises Investors of Unicycive Therapeutics, Inc. (UNCY) of an Upcoming Securities Class Action Deadline on November 2, 2026
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights